Answers are grounded in this paper and cite their sources.
We provide a comprehensive update on mitochondrial medicine therapies based on current evidence and our single-center clinical experience to support or refute their use, and provide detailed dosing guidelines, for the clinical management of mitochondrial disease. The overarching goal of empiric mitochondrial medicines is to utilize therapies with favorable benefit-to-risk profiles that may stabilize and enhance residual metabolic function to improve cellular resiliency and slow clinical disease progression and/or prevent acute decompensation.
No takes yet. Share an insight, caveat, or question.
Barcelos et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: